DUBLIN, December 12, 2014 /PRNewswire/ --
Dublin - Research and Markets (http://www.researchandmarkets.com/research/mwvkcf/dry_powder) has announced the addition of the "Dry Powder Inhalers to 2020" report to their offering.
(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )
Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions - aliments that require frequent drug administration for a protracted period of time.
While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers. The past two years has seen an increase in DPI product introductions, with four new combination products receiving marketing approval.
While evolving DPI technology and combination therapeutic products continue to have a significant impact on the treatment of upper respiratory diseases and conditions, dry powder inhalers are making strides in applications requiring the systemic delivery of both small and large molecule and engineered macromolecules for the treatment of a range of pathologies.
Highlights
Key Topics Covered:
Executive Summary
The DPI Market in 2014
Dry Powder Inhalation Technology
Commercial DPI Device Design Factors
DPI Device Assessments and Analysis
Therapeutic Market Analysis, Market Data and Forecasts
Market Factors
Company Profiles
For more information visit http://www.researchandmarkets.com/research/mwvkcf/dry_powder
Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net
Share this article